论文部分内容阅读
目的探讨氨氯地平阿托伐他汀钙片治疗高血压合并冠心病的临床效果。方法选取我院收治的108例高血压合并冠心病患者进行研究,将其划分为参照组和实验组两组。参照组54例患者给予硝苯地平缓释片治疗,实验组54例患者给予氨氯地平阿托伐他汀钙片治疗。对两组患者的临床疗效及发生的不良反应情况进行观察和比较。结果实验组临床有效率显著高于参照组,P<0.05;实验组不良反应发生率和参照组相比差异不显著,P<0.05。结论对高血压合并冠心病患者给予氨氯地平阿托伐他汀钙片进行治疗,可取得良好的效果,且安全性较高,不良反应少,值得临床推广。
Objective To investigate the clinical efficacy of amlodipine atorvastatin calcium in the treatment of patients with hypertension and coronary heart disease. Methods A total of 108 hypertensive patients with coronary heart disease admitted to our hospital were selected and divided into two groups: reference group and experimental group. In the reference group, 54 patients were treated with nifedipine sustained-release tablets, and 54 patients in the experimental group were given amlodipine atorvastatin calcium tablets. The clinical efficacy and adverse reactions of the two groups were observed and compared. Results The clinical effective rate in the experimental group was significantly higher than that in the reference group (P <0.05). There was no significant difference in the incidence of adverse reactions between the experimental group and the reference group (P <0.05). Conclusions The treatment of amlodipine atorvastatin in hypertensive patients with coronary heart disease can achieve good results with high safety and less adverse reactions, which is worthy of clinical promotion.